Fayez Sarofim & Co’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$205M Sell
1,700,379
-39,510
-2% -$4.56M 0.52% 46
2025
Q4
$183M Sell
1,739,889
-666,433
-28% -$62.6M 0.44% 50
2025
Q3
$202M Sell
2,406,322
-214,403
-8% -$17.7M 0.47% 54
2025
Q2
$207M Sell
2,620,725
-296,666
-10% -$23.6M 0.5% 53
2025
Q1
$262M Sell
2,917,391
-287,516
-9% -$26.8M 0.65% 45
2024
Q4
$319M Buy
3,204,907
+309,716
+11% +$31.9M 0.77% 39
2024
Q3
$329M Sell
2,895,191
-26,749
-0.9% -$3.18M 0.84% 35
2024
Q2
$362M Buy
2,921,940
+718,344
+33% +$92.5M 0.98% 29
2024
Q1
$291M Sell
2,203,596
-209,455
-9% -$25.8M 0.87% 35
2023
Q4
$303M Sell
2,413,051
-50,206
-2% -$5.21M 0.93% 34
2023
Q3
$254M Buy
2,463,257
+67,646
+3% +$7.29M 0.86% 35
2023
Q2
$276M Sell
2,395,611
-904,765
-27% -$103M 0.97% 31
2023
Q1
$351M Sell
3,300,376
-131,058
-4% -$14.1M 1.23% 27
2022
Q4
$381M Sell
3,431,434
-31,423
-0.9% -$3.21M 1.41% 27
2022
Q3
$298M Sell
3,462,857
-679
-0% -$60.6K 1.18% 30
2022
Q2
$316M Buy
3,463,536
+3,602
+0.1% +$319K 1.15% 32
2022
Q1
$284M Buy
3,459,934
+1,409
+0% +$111K 0.9% 38
2021
Q4
$265M Buy
3,458,525
+48,504
+1% +$3.86M 0.79% 41
2021
Q3
$256M Sell
3,410,021
-3,177
-0.1% -$242K 0.85% 39
2021
Q2
$265M Sell
3,413,198
-174,643
-5% -$13M 0.89% 38
2021
Q1
$264M Buy
3,587,841
+106,990
+3% +$7.89M 0.97% 37
2020
Q4
$272M Buy
3,480,851
+59,836
+2% +$4.58M 1.04% 35
2020
Q3
$271M Buy
3,421,015
+24,880
+0.7% +$1.95M 1.16% 30
2020
Q2
$251M Buy
3,396,135
+5,107
+0.2% +$384K 1.16% 33
2020
Q1
$249M Buy
3,391,028
+106,923
+3% +$8.4M 1.53% 27
2019
Q4
$285M Buy
3,284,105
+29,361
+0.9% +$2.41M 1.37% 28
2019
Q3
$261M Buy
3,254,744
+24,150
+0.7% +$1.94M 1.35% 28
2019
Q2
$258M Buy
3,230,594
+88,499
+3% +$6.78M 1.34% 27
2019
Q1
$249M Buy
3,142,095
+21,889
+0.7% +$1.64M 1.32% 28
2018
Q4
$227M Buy
3,120,206
+49,745
+2% +$3.51M 1.37% 26
2018
Q3
$208M Buy
3,070,461
+10,307
+0.3% +$657K 1.09% 32
2018
Q2
$177M Buy
3,060,154
+48,845
+2% +$2.76M 0.95% 36
2018
Q1
$157M Sell
3,011,309
-48,767
-2% -$2.63M 0.85% 38
2017
Q4
$164M Sell
3,060,076
-59,860
-2% -$3.32M 0.85% 38
2017
Q3
$191M Buy
3,119,936
+2,873
+0.1% +$174K 1% 34
2017
Q2
$191M Sell
3,117,063
-29,632
-0.9% -$1.8M 1.02% 32
2017
Q1
$191M Sell
3,146,695
-96,694
-3% -$5.87M 1.04% 30
2016
Q4
$182M Sell
3,243,389
-48,028
-1% -$2.81M 1% 32
2016
Q3
$196M Sell
3,291,417
-19,986
-0.6% -$1.17M 1.07% 29
2016
Q2
$182M Buy
3,311,403
+10,255
+0.3% +$546K 1% 31
2016
Q1
$167M Sell
3,301,148
-39,829
-1% -$1.95M 0.96% 36
2015
Q4
$168M Sell
3,340,977
-96,638
-3% -$4.87M 0.97% 34
2015
Q3
$162M Sell
3,437,615
-177,643
-5% -$9.44M 0.94% 36
2015
Q2
$196M Sell
3,615,258
-174,336
-5% -$9.78M 1% 34
2015
Q1
$208M Sell
3,789,594
-869,289
-19% -$49.2M 1.02% 34
2014
Q4
$253M Sell
4,658,883
-420,642
-8% -$23.4M 1.2% 25
2014
Q3
$287M Sell
5,079,525
-119,197
-2% -$6.69M 1.34% 22
2014
Q2
$287M Sell
5,198,722
-129,266
-2% -$7.05M 1.31% 24
2014
Q1
$288M Sell
5,327,988
-100,340
-2% -$5.2M 1.37% 22
2013
Q4
$259M Buy
+5,428,328
New +$248M 1.2% 30
2013
Q2
$253M Buy
+5,697,509
New +$254M 1.27% 24

Other funds holding MRK

Fayez Sarofim & Co's MRK Position: Q1 2026 in Review

Fayez Sarofim & Co reduced its Merck (MRK) stake by 2.3% in Q1 2026, selling an estimated $4.56M and leaving 1,700,379 shares worth $205M. The position accounts for 0.52% of the portfolio, ranked #46.

Fayez Sarofim & Co first reported a position in MRK in Q2 2013 and has held it in 51 quarters since. The position peaked at $381M in Q4 2022. 3,775 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Fayez Sarofim & Co held 1,700,379 shares of Merck worth $205M as of Q1 2026.
  • Fayez Sarofim & Co sold 39,510 Merck shares in Q1 2026, an estimated $4.56M.
  • Merck made up 0.52% of Fayez Sarofim & Co's portfolio in Q1 2026, its #46 holding.
  • Fayez Sarofim & Co first reported a position in Merck in Q2 2013 and has held it in 51 quarters since.
  • Fayez Sarofim & Co's Merck position peaked at $381M in Q4 2022.
  • 3,775 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Fayez Sarofim & Co's 13F filing for Q1 2026, filed 15 May 2026.